PharmaTutor
5 July 2016

Need Regulatory CMC Associate Manager at Novartis

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Post: Regulatory CMC Associate Manager-II / Manager (DP/DS)

Takeda Pharmaceutical Company Limited and Altos Therapeutics LLC jointly announced the companies have entered into a definitive agreement to further the development of Altos’s proprietary compound ATC-1906. Additionally, the agreement includes an exclusive option for Takeda to acquire Altos beginning on the date of the agreement and continuing for a period of time following the completion of ongoing phase 1 studies of ATC-1906. The parties envision future development of ATC-1906 for the treatment of gastroparesis (GP) and its symptoms.

Allergan plc, a leading global phbarmaceutical company, has received a positive opinion from the Swedish Medical Products Agency (MPA) for Belkyra (deoxycholic acid).  Belkyra will be the first prescription medicine to be licensed in Europe for the treatment of moderate to severe convexity or fullness associated with submental fat (often called double chin) in adults when the presence of submental fat has a psychological impact for the patient.

Array BioPharma announced the submission of a New Drug Application (NDA) for binimetinib in patients with advanced NRAS-mutant melanoma to the US Food and Drug Administration (FDA). The submission is based on results of the pivotal phase 3 NEMO (NRAS MELANOMA AND MEK INHBITOR) study, which found binimetinib significantly extended median progression-free survival (PFS), the study's primary endpoint, as compared with dacarbazine.

AstraZeneca announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, Cardiovascular and Metabolic disease and Oncology. The agreements include two of AstraZeneca’s potential new medicines for dermatitis and psoriasis, allowing the Company to further simplify and sharpen focus on innovative new medicines in the main therapy areas. 

Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, announced that its lead product, ATIR101, has been granted an expansion to its existing Orphan Drug designation (ODD) by the European Medicines Agency (EMA) to include treatment in a hematopoietic stem cell transplantation (HSCT).

[adsense:336x280:8701650588]

4 July 2016
Mead Johnson looking for Nutrition Executive

Mead Johnson Nutrition is a global leader in infant and children's nutrition. We are best known for our infant formulae like Enfamil® and Enfapro®, and children's nutritional products like Enfagrow®, Enfakid®, EnfaSchool®, and Sustagen® in Asia, and Choco Milk® and Cal-C-Tose® in Mexico and Latin America. Our company was founded more than 100 years ago, in the year 1905, by Edward Mead Johnson. Sr. E. Mead launched his business after leaving Johnson & Johnson, which he co-founded with his brothers. MJN has been committed from its very beginning to earning the trust of parents and health care professionals by offering scientific evidence of the benefits of our products. That commitment, driven by the pride and passion of our workforce of approximately 5,600 people, is evident today throughout the world. We manufacture and market more than 70 products in over 60 countries in North America, Latin America, Europe, and Asia-Pacific, and we operate major manufacturing facilities in every region where we conduct business. Our global headquarters are in Chicago and Asia-Pac headquarters are in Bangkok. For the year 2009, our sales turnover was US$ 2.9 Billion, and we are listed on the New York stock exchange.

Post : Nutrition Executive

4 July 2016
Wanted Principal, Professor, Associate Professor, Assistant Professor in College of Pharmacy, Medha

The College of Pharmacy, Medha was established in the year 2003 under the auspices of Meruling Shikshan Sanstha, Dare Khurd (Satara). The College is recognized by The Government of Maharashtra and affiliated to Shivaji University, Kolhapur, approved by the Pharmacy Council of India (PCI) and All India Council of Technical Education (AICTE), New Delhi. It is located at Medha in a sprawling pollution free campus which is 20 KM away from Satara City. The College is housed in a campus with most conducive atmosphere for academic preference. Vision Our Institute will serve as a focus towards the pinnacle of academic leadership for the profession of Pharmacy. Our Institute will elevate with a culture of mutual care and commitment by providing a satisfying and exciting work environment, continuous learning and research opportunities. Our Institute will elevate the culture of mutual care and commitment by providing a satisfying and exciting study environment, continuous learning and research opportunities.

Applications are invited from eligible candidates for the following posts to be filled in college’s B. Pharmacy section.

Post : Principal, Professor, Associate Professor, Assistant  Professor

4 July 2016
Opportunity to work as Manager-Trial Management in Novartis

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Post : Manager-Trial Management

4 July 2016
Job at Novo Nordisk as Senior Manager - FP&A - Marketing Analytics

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within Haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in more than 190 countries Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B).

Post : Senior Manager - FP&A - Marketing Analytics